Pediatric Inflammatory Myofibroblastic Tumors of the Airway: Two Case Reports with Varying Clinical Presentation

Document Type: Case Report


1 Department of Pediatric Hematology and Oncology, Kanchi Kamakoti Childs Trust Hospital And The Childs Trust Medical Research Foundation, Nungambakkam, Chennai – 600034,Tamil Nadu State, India.

2 Department of Pediatric ENT, Kanchi Kamakoti Childs Trust Hospital And The Childs Trust Medical Research Foundation, Nungambakkam, Chennai – 600034,Tamil Nadu State, India.

3 Department of Pathology, Kanchi Kamakoti Childs Trust Hospital And The Childs Trust Medical Research Foundation, Nungambakkam, Chennai – 600034,Tamil Nadu State, India.


An inflammatory myofibroblastic tumor (IMT) is a rare tumor of intermediate malignant potential. It may occur in a wide range of anatomical locations. One-third are found in the respiratory tract. We report two cases of IMT of the airway diagnosed at our institution.
Case Report:
Case 1: A 6-year-old male child presented with a 1-month history of hoarseness of the voice. On evaluation, a polypoid nodule was noted in the right vocal cord which was excised through the endolaryngeal route. Histopathology was suggestive of anaplastic lymphoma kinase (ALK)-negative IMT. He presented with recurrence after 4 months, for which he underwent endolaryngeal reexcision and tracheostomy for airway protection. A third recurrence after 6 months was managed with laser excision, and the patient was started on oral celecoxib. After 1.5 years of follow up, endoscopic examination showed no recurrence, and celecoxib was continued. Case 2: A 7-year-old male child presented with cough and respiratory distress. Bronchoscopy and high resolution computed tomography showed a polypoidal lesion with calcification arising from the left anterolateral wall of the trachea with significant narrowing of the lumen. The patient underwent biopsy followed by endoscopic excision, and was diagnosed with IMT. Currently the patient is under follow up with no recurrence.
IMT indicates a proliferative myofibroblastic growth. Surgical resection should be recommended for all lesions if not prohibited by anatomic location or morbidity. Patients should be followed up closely for recurrence. In most cases, complete surgical excision will suffice; however multiple recurrences can be managed with chemotherapy. These two cases highlight the importance of a multidisciplinary approach in rare tumors in difficult anatomical locations.


Main Subjects

1. Coffin CM, Hornick JL, Fletcher CDM. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohisto- chemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 2007; 31:509–20.

2. Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 1995;19(8):859–72.

3. Mehta B, Mascarenhas L, Zhou S, Wang L, Venkatramani R. Inflammatory Myofibroblastic Tumors in Childhood. Pediatr Hematol Oncol 2013; 30:640–5.

4. Johnson K, Notrica DM, Carpentieri D, Jaroszewski D, Henry MM. Successful Treatment of Recurrent Pediatric Inflammatory Myofibroblastic Tumor in a Single Patient With a Novel Chemotherapeutic Regimen Containing Celecoxib. J Pediatr Hematol Oncol 2013;35:414-16.

5. Anthony PP. Inflammatory pseudotumor (plasma cell granuloma) of lung, liver and other organs. Histopathology. 1993;23:501–503.

6. Brodlie M, Barwick SC, Wood KM, McKean MC, Welch A. Inflammatory myofibroblastic tumours of the respiratory tract: paediatric case series with varying clinical presentations. J Laryngol Otol 2011; 125: 865–8.

7. Hoover SV, Granston AS, Koch DF, et al. Plasma cell granuloma of the lung, response to radiation therapy. Cancer 1976;39:123–5.

8. Kovach SJ, Fischer AC, Katzman PJ, Salloum RM, Ettinghausen SE, Madeb R, et al. Inflammatory myofibroblastic tumors. J Surg Oncol 94:385–91.

9. Uchida DA, Hawkins JA, Coffin CM, Grimmer JF. Inflammatory myofibroblastic tumor in the airway of a child. Ann Thorac Surg 2009;87:

10. Wenig BM, Devaney K, Bisceglia M. Inflammatory myofibroblastic tumor of the larynx. A clinicopathologic study of eight cases simulating a malignant spindle cell neoplasm. Cancer 1995; 76: 2217–29.

11. Alhumaid H, Bukhari M, Rikabi A, Farahat M, Mesallam TA, Malki KH, et al. Laryngeal myofibroblastic tumor: case series and literature review. Int J Health Sci (Qassim). 2011; 5:187–95.

12. Das Purkayastha PK, Hartley BE, Sebire NJ. Airway obstruction due to a retro-tracheal inflammatory myofibroblastic tumour in a 19-month old boy. Int J Pediatr Otorhinolaryngol. Extra 2009; 4:25–8.

13. Kumar S, Gupta AK, Kakkar N. Inflammatory myofibroblastic tumor larynx mimicking laryngeal papillomatosis. Int J Pediatr Otorhinolaryngol Extra 2009;4 :42–4.

14. Mandelbaum I, Brashear RE, Hull MT. Surgical treatment and course of pulmonary pseudotumor (plasma cell granuloma). J Thorac Cardiovasc Surg 1981; 82:77–82.

15. Corsi A, Ciofalo A, Leonardi M et al. Recurrent inflammatory myofibroblastic tumor of the glottis mimicking malignancy. Am J Otolaryngol 1997; 18:121–6.

16. Przkora R, Bolder U, Schwarz S, Jauch KW, Spes J, Andreesen R et al. Regression of nonresectable inflammatory myofibroblastic tumours after treatment with nonsteroidal anti-inflammatory drugs. Eur J Clin Invest 2004; 34: 320–1.

17. Hakozaki Y, Katou M, Nakagawa K, Shirahama T, Matsumoto T. Improvement of inflammatory pseudotumor of the liver after nonsteroidal antiinflammatory agent therapy. Am J Gastroenterol 1993; 88:1121–2.

18. Yun-Lu Tao, Zhen-Jun Wang, Jia-Gang Han, Wei P. Inflammatory myofibroblastic tumor successfully treatedwith chemotherapy and nonsteroidals: A case report. World J Gastroenterol2012; 18:7100–3.

19. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306–11.

20.  Butrynski JE, D’Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010; 363: 1727–33.

21. Giuriato S, Faumont N, Bousquet E, Foisseau M, Bibonne A, Moreau M et al. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biol Ther.2007; 6: 1318–23.